Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Inventory (2016 - 2025)

Historic Inventory for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $4.0 million.

  • Cytosorbents' Inventory rose 2322.35% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 2322.35%. This contributed to the annual value of $2.7 million for FY2024, which is 1904.18% down from last year.
  • Cytosorbents' Inventory amounted to $4.0 million in Q3 2025, which was up 2322.35% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Inventory registered a high of $5.4 million during Q1 2022, and its lowest value of $1.7 million during Q1 2023.
  • Over the past 5 years, Cytosorbents' median Inventory value was $3.5 million (recorded in 2022), while the average stood at $3.6 million.
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 12358.96% in 2021, then crashed by 6831.01% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Inventory stood at $4.8 million in 2021, then decreased by 27.37% to $3.5 million in 2022, then decreased by 2.48% to $3.4 million in 2023, then decreased by 19.04% to $2.7 million in 2024, then soared by 46.43% to $4.0 million in 2025.
  • Its Inventory stands at $4.0 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.0 million for Q1 2025.